Showing 2712 results
-
Ad hoc release /Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development…
-
Ad hoc release /Novartis ernennt eine erfahrene Pharma-Führungskraft mit starken Marketingfähigkeiten, um das Onkologiegeschäft weiter zu entwickeln Novartis ernennt ad interim Leiter für die Global Drug…
-
Press release /Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
-
Press release /Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab…
-
Press release /New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving…
-
Press release /Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
-
Press release /NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
-
Press release /Heads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image…
-
Press release /Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries Retrospective…
-
Press release /Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…